In the M118 EMINENCE study, the lowest-dose arm (50 IU/kg) paradoxically had the best efficacy (#msg-48837450, #msg-48837695), which is why I’m pretty sure MNTA will advance this dose into phase-2b. Whether the other doses tested in phase-2b will be 75, 100, both, or something else is hard to say until we know what the patient pool will be (see below).
i think comparator will be angiomax in a PCI setting
MNTA will IMO likely aim for a medium-risk patient pool in phase-2b, whether or not the trial(s) are in the PCI setting. The EMINENCE study was limited to patients with stable angina, which is the lowest-risk group, so it would be helpful to show that M118 works in patents with unstable angina or NSTEMI.
Market Data 
Markets 
AI
